论文部分内容阅读
目的:探究分析使用尼莫同治疗外伤性蛛网膜下腔出血的临床疗效。方法:采用回顾性分析的方法,分析了我院在2013年4月1日至2014年4月1日间收治的68例外伤性蛛网膜下腔出血的患者的临床资料,根据治疗方案的不同,随机分成对照组和实验组,每组各34例,对照组选用常规的对症治疗,实验组在对照组的基础上,予以尼莫同,观察比较两组患者的治疗情况及并发症发生情况。结果:实验组的治疗有效率达88.24%,远远高于对照组的67.65%,实验组发生再出血、脑积水等并发症的患者也明显少于对照组,且两组数据差异符合统计学的意义,P<0.05。结论:尼莫同可以有效治疗外伤性蛛网膜下腔出血,减少再出血、迟发型脑血管痉挛等并发症发生的概率,值得临床广泛推广使用。
Objective: To investigate the clinical efficacy of nimodipine in the treatment of traumatic subarachnoid hemorrhage. Methods: The clinical data of 68 patients with traumatic subarachnoid hemorrhage treated in our hospital from April 1, 2013 to April 1, 2014 were retrospectively analyzed. According to the different treatment plans , Were randomly divided into control and experimental groups, 34 cases in each group, the control group used conventional symptomatic treatment, the experimental group in the control group, based on the Nemo, observed and compared the two groups of patients with treatment and complications . Results: The effective rate of the experimental group was 88.24%, which was much higher than that of the control group (67.65%). The experimental group had fewer complications such as hemorrhage and hydrocephalus than the control group, and the difference between the two groups was statistically significant The significance of learning, P <0.05. Conclusion: Nemo can effectively treat the traumatic subarachnoid hemorrhage, reduce the probability of re-bleeding, delayed cerebral vasospasm and other complications, which is worthy of wide application in clinic.